+34 679 490 537info@nanbiosis.com

Posts on Jan 1970

3D cross-correlation dynamic light scattering (DLS) spectrometer of NANBIOSIS U12 has been upgraded

The 3D cross-correlation dynamic light scattering (DLS) spectrometer of NANBIOSIS U12 Nanostructured liquid characterization unit has been upgraded with a new goniometer and last generation laser detectors and beam splitters that allow to extend the scattering angle detection range to 10-150 degrees, and enables measurements in shorter scattering lengths for highly turbid and/or concentrated samples. Non-ergodic samples (e.g. gels) can also be measured with the new configuration

The upgrade has been funded by CSIC through the grant “Special fund for the support of Scientific and Technical Services 2018” (02045)

Read More

Why peripheral blood lymphocyte alterations can be good biomarkers to predict myocardial infarction severity

Researchers of CCMIJU led by Verónica Crisóstomo, Scientific Director of NANBIOSIS U24 Medical imaging, and Javier García Casado Scientific Director of NANBIOSIS U14 Cell Therapy unit have carried out a study study aimed to identify which are the very early immune-related biomarkers that may be used as predictors of myocardial infarction severity.

Experimental studies have been conducted by NANBIOSIS Units 14, 21, 22 and 24 of the CCMIJU, clinical test lab, animal housing, experimental operating room and medical imaging tecniciansare are recognized in the acknowledgement and funding sections of the article.

Article of reference:

Esther López, Francisco Miguel Sánchez-Margallo, Verónica Álvarez, Rebeca Blázquez, Federica Marinaro, Ana Abad, Helena Martín, Claudia Báez,Virginia Blanco,Verónica Crisóstomo and Javier García Casado “Identification of very early inflammatory markers in a porcine myocardial infarction model” BMC Veterinary Research 2019-15:91

Read More

New tensiometer for NANBIOSIS Unit 12

The new Biolin Sigma 701 has replaced the previos KSV Sigma 700. in the equipment of NANBIOSIS U12 Nanostructured liquid characterization unit

With this new tensiometer automated and high precision measurement of surface and interfacial tensions, contact angles and critical micelle concentrations will be obtained.

The purchase of the new tensiometer has been co-funded by the CSIC through a grant received from the Scientific and Technical Services support (MEC1372).

Read More

Infertility: Exosomal microRNAs in seminal plasma as sensitive and specific biomarkers of the presence of testicular spermatozoa for azoospermia

NANBIOSIS ICTS coordination equipment has recently received from researchers of Human Molecular Genetics Group of Bellvitge Biomedical Research Institute (IDIBELL) a publication mentioning NANBIOSIS in the Acknowledgements for its participation in the results of its investigations. The article has been publish by the journal Human Reproduction of OXFORD UNIV PRESS  with Quartile 1/ Decile 1.

The study carried out by  Maria Barcelo, Ana Mata, Lluís Bassas, and Sara Larriba demonstrates the potential of several miRNAs contained in small extracellular vesicles (sEVs) of seminal fluid as sensitive and specific biomarkers for selecting those azoospermic individuals with real chances of obtaining spermatozoa from the testicular biopsy. The nanoparticle tracking analysis was performed by the ICTS NANBIOSIS  U6 Biomaterial Processing and Nanostructuring Unit.

Article of reference:

Maria Barceló, Ana Mata, Lluís Bassas and Sara Larriba, Exosomal microRNAs in seminal plasma are markers of the origin of azoospermia and can predict the presence of sperm in testicular tissue Human Reproduction, pp. 1–12, 2018doi:10.1093/humrep/dey072

Read More

NANOMOL group, coordinator of NANBIOSIS Unit 6 collaborates with the VHIR in the developement of a new nanomedicine for the treatment of a childhood cancer

Within the MOTHER project (Molecule-based materials and supramolecular organizations for therapy, diagnosis and tissue engineering), the NANOMOL group from ICMAB collaborates with the Vall d’Hebron Institute of Research (VHIR), on the developement of a new nanomedicine for the treatment of high risk neuroblastoma, one of the most typical childhood cancers. Now, researchers from VHIR have identified new microRNAs that reduce the progression of this type of cancer.

The participation of NANOMOL group and NANBIOSIS unit 6 Biomaterial Processing and Nanostructuring Unit, as experts in nanoparticles and nanovesciles for nanomedicine, is on the synthesis of the adequate nanocapsules to protect, stabilize and direct this microRNAs molecules to the cancer tumours. The near future goal is to be able to administer the identified microRNAs for the treatment of high-risk neuroblastoma.

For further information

Read More